Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth - PubMed (original) (raw)
Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth
Mamoru Fujita et al. Carcinogenesis. 2005 Feb.
Abstract
Angiotensin II is a multi-functional bioactive peptide and recent reports have suggested that angiotensin II is a proangiogenic growth factor. A retrospective cohort study revealed that angiotensin converting enzyme inhibitors decreased cancer risk, however, the precise mechanism is unknown. We hypothesized that endogenous angiotensin II plays a crucial role in tumor-associated angiogenesis. Tumors implanted in the subcutaneous tissue of wild-type mice developed intensive angiogenesis with vascular endothelial growth factor (VEGF) induction in tumor stroma. AT1a receptor (AT1a-R), but not AT1b receptor or AT2 receptor was expressed in tumor stroma and systemic administration of an AT1-R antagonist reduced tumor-associated angiogenesis and VEGF expression in tumor stroma. Angiotensin II up-regulates VEGF expression through the pathway including protein kinase C, AP-1 and NF-kappaB in fibroblasts, the major cellular component of tumor stroma. VEGF is a major determinant of tumor-associated angiogenesis in the present model, since angiogenesis was markedly reduced by either a VEGF neutralizing antibody or a VEGF receptor kinase inhibitor. Compared with the wild-type, tumor-associated angiogenesis was reduced in AT1a-R null mice, with reduced expression of VEGF in the stroma, and this reduction in AT1a-R null mice was not inhibited by an AT1-R antagonist. These suggest that host stromal VEGF induction by AT1a-R signaling is a key regulator of tumor-associated angiogenesis and tumor growth. AT1a-R signaling blockade may be a novel and effective therapeutic strategy against cancers.
Similar articles
- Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis.
Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M. Fujita M, et al. Biochem Biophys Res Commun. 2002 Jun 7;294(2):441-7. doi: 10.1016/S0006-291X(02)00496-5. Biochem Biophys Res Commun. 2002. PMID: 12051731 - Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression.
Ohnuma Y, Toda M, Fujita M, Hosono K, Suzuki T, Ogawa Y, Amano H, Kitasato H, Hayakawa K, Majima M. Ohnuma Y, et al. Biomed Pharmacother. 2009 Feb;63(2):136-45. doi: 10.1016/j.biopha.2007.11.005. Epub 2007 Dec 26. Biomed Pharmacother. 2009. PMID: 18691848 - Angiotensin II type 1A receptor signaling facilitates tumor metastasis formation through P-selectin-mediated interaction of tumor cells with platelets and endothelial cells.
Amano H, Ito Y, Ogawa F, Eshima K, Suzuki T, Oba K, Matsui Y, Kato S, Fukui T, Nakamura M, Kitasato H, Fukamizu A, Majima M. Amano H, et al. Am J Pathol. 2013 Feb;182(2):553-64. doi: 10.1016/j.ajpath.2012.10.026. Epub 2012 Dec 3. Am J Pathol. 2013. PMID: 23219751 - [Endothelin-1, angiotensin II and cancer].
Cazaubon S, Deshayes F, Couraud PO, Nahmias C. Cazaubon S, et al. Med Sci (Paris). 2006 Apr;22(4):416-22. doi: 10.1051/medsci/2006224416. Med Sci (Paris). 2006. PMID: 16597412 Review. French. - [Stimulatory effects of angiotensin II on angiogenesis].
Sugawara A, Ito S. Sugawara A, et al. Nihon Rinsho. 2006 Jul;64 Suppl 5:67-9. Nihon Rinsho. 2006. PMID: 16897854 Review. Japanese. No abstract available.
Cited by
- Survival impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in head and neck cancer.
Stokes WA, Molina E, McDermott JD, Morgan RL, Bickett T, Fakhoury KR, Amini A, Karam SD. Stokes WA, et al. Head Neck. 2021 Nov;43(11):3255-3275. doi: 10.1002/hed.26809. Epub 2021 Jul 21. Head Neck. 2021. PMID: 34289190 Free PMC article. - Involvement of local renin-angiotensin system in immunosuppression of tumor microenvironment.
Nakamura K, Yaguchi T, Ohmura G, Kobayashi A, Kawamura N, Iwata T, Kiniwa Y, Okuyama R, Kawakami Y. Nakamura K, et al. Cancer Sci. 2018 Jan;109(1):54-64. doi: 10.1111/cas.13423. Epub 2017 Nov 9. Cancer Sci. 2018. PMID: 29034589 Free PMC article. - Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis.
Amano H, Ito Y, Suzuki T, Kato S, Matsui Y, Ogawa F, Murata T, Sugimoto Y, Senior R, Kitasato H, Hayashi I, Satoh Y, Narumiya S, Majima M. Amano H, et al. Cancer Sci. 2009 Dec;100(12):2318-24. doi: 10.1111/j.1349-7006.2009.01322.x. Epub 2009 Aug 25. Cancer Sci. 2009. PMID: 19799610 Free PMC article. - Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis.
Chin HJ, Oh SW, Goo HS, Oh J, Noh JW, Cho JT, Na KY, Kim S, Chae DW; Members of The PREMIER Group. Chin HJ, et al. J Korean Med Sci. 2011 Jan;26(1):59-66. doi: 10.3346/jkms.2011.26.1.59. Epub 2010 Dec 22. J Korean Med Sci. 2011. PMID: 21218031 Free PMC article. - Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice.
Cheng XW, Song H, Sasaki T, Hu L, Inoue A, Bando YK, Shi GP, Kuzuya M, Okumura K, Murohara T. Cheng XW, et al. Hypertension. 2011 May;57(5):981-9. doi: 10.1161/HYPERTENSIONAHA.110.168385. Epub 2011 Apr 4. Hypertension. 2011. PMID: 21464389 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials